News
EUnetHTA Magazine – Winter 2021 – now available
We are please to finally publish another issue of the EUnetHTA Magazine, a collection of articles submitted by members and stakeholders that deal with HTA
EUnetHTA – Open Letter of Comment
This is an open letter, written by the Chair of the EUnetHTA Executive Board, Niklas Hedberg. It expresses commentary on the role of EUnetHTA within
Minutes of EMA/EUnetHTA virtual meeting
We are pleased to publish the minutes of the 13 July 2020 meeting held between the European Medicines Agency (EMA) and EUnetHTA. The meeting covered
EMA-EUnetHTA Bilateral Meeting July 2020 – minutes now available
We are pleased to publish the minutes of the 13 July 2020 meeting held between the European Medicines Agency (EMA) and EUnetHTA. The meeting covered
RCROT02 – Rapid Collaborative Review on the diagnostic accuracy of molecular methods that detect the presence of SARS-CoV-2 virus in people with suspected COVID-19 – report now available
EUnetHTA is pleased to announce that the “Rapid Collaborative Review on the diagnostic accuracy of molecular methods that detect the presence of SARS-CoV-2 virus in
OTCA28 – ‘Lung cancer screening in risk groups’ – final assessment now available
We are pleased to announce that the collaborative assessment, OTCA28 – ‘Lung cancer screening in risk groups’ – is now available. The aim of this
PTJA10 – Crizanlizumab for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and older – Final assessment now available
This is the pharmaceutical Joint Assessment PTJA10 – Crizanlizumab for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and older.
PTRCR18 – Dexamethasone for the treatment of hospitalised patients with COVID-19 – Final Rapid Collaborative Review now available.
This is the second pharmaceutical Rapid Collaborative Review (PTRCR18) published by EUnetHTA. This report describes dexamethasone for the treatment of COVID-19 patients. In September, 2020,
Patient group input requested for a new Joint Assessment on a medicinal product for cerebral adrenoleukodystrophy (CALD).
This is the second pharmaceutical Rapid Collaborative Review (PTRCR18) published by EUnetHTA. This report describes dexamethasone for the treatment of COVID-19 patients. In September, 2020,
PTRCR15 – remdesivir for the treatment of COVID-19. First update, December 2020.
In June, 2020, the European Commission granted marketing authorisation for Veklury® (remdesivir) for the treatment of Covid-19. This is the first update on the pharmaceutical
